Shares of McKesson Co. (NYSE:MCK) have received a consensus recommendation of “Hold” from the fourteen research firms that are covering the company, MarketBeat Ratings reports. Two research analysts have rated the stock with a sell rating, six have issued a hold rating and five have assigned a buy rating to the company. The average 12-month price objective among brokers that have issued ratings on the stock in the last year is $131.10.
A number of equities analysts recently weighed in on MCK shares. Zacks Investment Research lowered McKesson from a “hold” rating to a “sell” rating in a research report on Wednesday, April 3rd. ValuEngine lowered McKesson from a “sell” rating to a “strong sell” rating in a research report on Friday, March 1st. Finally, Wolfe Research initiated coverage on McKesson in a research report on Tuesday, April 2nd. They issued an “outperform” rating for the company.
In related news, CFO Britt J. Vitalone sold 832 shares of the stock in a transaction dated Friday, May 24th. The stock was sold at an average price of $129.17, for a total value of $107,469.44. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, EVP Lori A. Schechter sold 2,766 shares of the stock in a transaction dated Friday, May 10th. The stock was sold at an average price of $133.59, for a total value of $369,509.94. The disclosure for this sale can be found here. Over the last three months, insiders sold 6,174 shares of company stock valued at $804,583. Company insiders own 0.87% of the company’s stock.
Shares of NYSE:MCK traded up $1.42 during midday trading on Wednesday, reaching $134.02. The company had a trading volume of 1,077,613 shares, compared to its average volume of 1,519,446. The company has a quick ratio of 0.58, a current ratio of 1.02 and a debt-to-equity ratio of 0.88. McKesson has a 1-year low of $106.11 and a 1-year high of $151.24. The firm has a market capitalization of $25.19 billion, a price-to-earnings ratio of 9.88, a price-to-earnings-growth ratio of 1.31 and a beta of 1.07.
McKesson (NYSE:MCK) last released its quarterly earnings results on Wednesday, May 8th. The company reported $3.69 earnings per share for the quarter, beating the Zacks’ consensus estimate of $3.66 by $0.03. McKesson had a return on equity of 29.02% and a net margin of 0.02%. The business had revenue of $52.43 billion during the quarter, compared to analyst estimates of $53.14 billion. During the same quarter last year, the company posted $3.49 EPS. McKesson’s revenue for the quarter was up 1.6% on a year-over-year basis. Equities analysts predict that McKesson will post 14.14 earnings per share for the current year.
The firm also recently disclosed a quarterly dividend, which will be paid on Monday, July 1st. Investors of record on Monday, June 3rd will be paid a $0.39 dividend. This represents a $1.56 annualized dividend and a yield of 1.16%. The ex-dividend date is Friday, May 31st. McKesson’s dividend payout ratio is currently 11.50%.
McKesson Corporation provides pharmaceuticals and medical supplies in the United States and internationally. It operates in three segments: U.S. Pharmaceutical and Specialty Solutions, European Pharmaceutical Solutions, and Medical-Surgical Solutions. The company distributes branded, generic, specialty, biosimilar, and over-the-counter pharmaceutical drugs, as well as other healthcare-related products; and offers practice management, technology, clinical support, and business solutions to community-based oncology and other specialty practices.
Featured Story: 52-Week High/Low
Receive News & Ratings for McKesson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for McKesson and related companies with MarketBeat.com's FREE daily email newsletter.